Zepbound (tirzepatide) is FDA-approved and considered safe for most adults with obesity or excess weight, but it does carry real risks that vary from common and mild to rare and serious. The FDA approved it in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. Like any prescription medication, its safety depends on your individual health history and how well you tolerate the drug as your dose gradually increases.
Common Side Effects
The most frequent side effects are gastrointestinal, and they’re common enough that you should expect at least some stomach issues, especially early on. In clinical trials, nausea affected 20% to 33% of people taking Zepbound at moderate to high doses, compared to just 6% to 10% on placebo. Diarrhea, vomiting, and constipation were also reported at elevated rates. For most people, these symptoms are worst during the first few weeks on a new dose and tend to fade as the body adjusts.
Zepbound’s dosing schedule is specifically designed to reduce these effects. You start at the lowest dose (2.5 mg weekly) for four weeks before moving up. Each increase is just 2.5 mg, with at least four weeks between steps. This slow escalation gives your digestive system time to adapt. If side effects are still significant at a given dose, your prescriber can keep you there longer before increasing.
The Boxed Warning: Thyroid Tumors
Zepbound carries the FDA’s most serious type of warning, a boxed warning, related to thyroid C-cell tumors. In animal studies, tirzepatide caused thyroid tumors in rats at doses relevant to human use. Whether this translates to humans is unknown, and no confirmed cases have emerged in clinical trials. Still, the FDA treats this risk conservatively.
Because of this warning, Zepbound is strictly off-limits if you have a personal or family history of medullary thyroid carcinoma (a rare type of thyroid cancer) or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2. These are the only absolute contraindications. If you don’t have either, the thyroid risk is theoretical based on animal data, not something observed in people so far. That said, you should be aware of symptoms like a persistent lump in your neck, difficulty swallowing, or unexplained hoarseness, and report them promptly.
Pancreatitis and Gallbladder Problems
Acute pancreatitis, an inflammation of the pancreas that causes severe abdominal pain, occurred in about 0.2% of people taking Zepbound in clinical trials. That’s the same rate as in people taking a placebo, which suggests the drug doesn’t meaningfully raise this risk. Still, the prescribing label warns prescribers to watch for it, particularly persistent severe abdominal pain that may radiate to the back.
Gallbladder problems, including gallstones and inflammation, are a known concern with rapid weight loss in general, not just with this medication. If you develop sudden pain in your upper right abdomen, especially after eating, that warrants evaluation. Rapid weight loss of any kind increases the rate at which cholesterol concentrates in bile, which can trigger gallstone formation.
Mental Health Considerations
Early reports raised questions about whether GLP-1 receptor agonists (the drug class Zepbound belongs to) might be linked to suicidal thoughts or depression. The FDA investigated and found no evidence that these medications cause suicidal thoughts or behavior. Reviews of clinical trial data and observational studies showed no association. However, the FDA noted that because the absolute number of such events in trials was small, a very small risk can’t be definitively ruled out.
The prescribing label does recommend monitoring for new or worsening depression, suicidal thoughts, or unusual mood changes. This language appears on most weight-loss medications, not just Zepbound, based on historical experience with older weight-loss drugs. If you have a history of depression or mood disorders, it’s worth keeping track of how you feel, particularly during dose changes.
Effects on Other Medications
Zepbound slows down how quickly your stomach empties, which is part of how it reduces appetite. But this also means oral medications you take at the same time may be absorbed differently. The most important practical example: oral hormonal birth control pills may become less effective.
If you use oral contraceptives, the recommendation is to switch to a non-oral method (like a patch, ring, IUD, or implant) or add a barrier method like condoms for four weeks after starting Zepbound and for four weeks after each dose increase. This delay in absorption is strongest with the first dose and diminishes over time. Hormonal contraceptives that aren’t swallowed, like patches or IUDs, aren’t affected.
If you take any medication with a narrow window between an effective dose and a harmful one (blood thinners like warfarin, for example), your levels should be monitored more closely while starting or adjusting Zepbound.
Pregnancy and Breastfeeding
Zepbound is not recommended during pregnancy. Weight loss itself offers no benefit during pregnancy and could potentially harm a developing baby. The drug should be discontinued at least two months before a planned pregnancy, given that tirzepatide stays in the body for some time after the last injection. There is no adequate human data on its use during breastfeeding, so the decision to use it while nursing requires weighing the lack of safety data against the benefits.
One underappreciated detail: because Zepbound can reduce the effectiveness of oral birth control (as described above), unintended pregnancy is a real concern for women starting the medication. This makes the contraception guidance especially important to follow closely during the early weeks of treatment.
Kidney Function and Dehydration
The nausea, vomiting, and diarrhea that can accompany Zepbound may lead to dehydration, and dehydration can stress the kidneys. This is particularly relevant if you already have reduced kidney function. There’s no evidence that tirzepatide directly harms the kidneys, but the indirect effects of fluid loss mean you should stay well hydrated and report persistent vomiting or diarrhea. Your prescriber may check kidney function if you’re experiencing significant GI symptoms.
Who Should Be More Cautious
Beyond the hard contraindications (medullary thyroid carcinoma history and MEN 2), several groups need closer monitoring while using Zepbound:
- People with a history of pancreatitis should discuss whether the potential benefit outweighs even a small theoretical risk of recurrence.
- People with type 2 diabetes on insulin or other blood-sugar-lowering medications may need dose adjustments to avoid dangerously low blood sugar, since Zepbound also lowers glucose levels.
- People with diabetic retinopathy should have their eye health monitored, as rapid improvements in blood sugar control can temporarily worsen this condition.
- People taking medications affected by absorption timing should work with their prescriber to adjust schedules or monitor drug levels.
For the majority of people who meet the BMI criteria and don’t have contraindications, Zepbound’s safety profile in clinical trials was manageable. The side effects are real and sometimes uncomfortable, particularly the GI symptoms, but they tend to improve with time and are rarely dangerous. The serious risks, like pancreatitis and thyroid concerns, are either very rare or still theoretical in humans. The gradual dose escalation built into the prescribing schedule exists specifically to make the transition safer and more tolerable.